anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
One multicenter, randomized, double-blind trial compared CAFCIT (caffeine citrate) to placebo in eighty-five (85) preterm infants (gestational age 28 to <33 weeks) with apnea of prematurity. Apnea of prematurity was defined as having at least 6 apnea episodes of greater than 20 seconds duration in a 24-hour period with no other identifiable cause of apnea. A 1 mL/kg (20 mg/kg caffeine citrate providing 10 mg/kg as caffeine base) loading dose of CAFCIT was administered intravenously, followed by a 0.25 mL/kg (5 mg/kg caffeine citrate providing 2.5 mg/kg of caffeine base) daily maintenance dose administered either intravenously or orally (generally through a feeding tube). The duration of treatment in this study was limited to 10 to 12 days. The protocol allowed infants to be "rescued" with open-label caffeine citrate treatment if their apnea remained uncontrolled during the double-blind phase of the trial.

The percentage of patients without apnea on day 2 of treatment (24 to 48 hours after the loading dose) was significantly greater with CAFCIT than placebo. The following table summarizes the clinically relevant endpoints evaluated in this study:

1 Of 85 patients who received drug, 3 were not included in the efficacy analysis because they had <6 apnea episodes/24 hours at baseline.

In this 10 to 12 day trial, the mean number of days with zero apnea events was 3 in the CAFCIT group and 1.2 in the placebo group. The mean number of days with a 50% reduction from baseline in apnea events was 6.8 in the CAFCIT group and 4.6 in the placebo group.
Alzheimer's disease (AD) is a complex neurodegenerative disease without any effective preventive or therapeutic drugs. Natural products with stable structures and pharmacological characteristics are valuable sources for the development of novel drugs for many complex diseases. This study aimed to discover potential natural compounds for the treatment of AD using new technologies and methods and explore the efficacy and mechanism of candidate compounds. AD-related large-scale genetic datasets were collated to construct disease-PPIs and natural products were collected from six databases to construct compound-protein interactions (CPIs). Potential relationships between natural compounds and AD were predicted via network proximity and gene enrichment analyses. Then, five AD-related cell models and d-galactose-induced aging rat model were established to evaluate the neuroprotective effects of candidate compounds in vitro and in vivo. We identified that 267 natural compounds were predicted to have close connections with AD and 19 compounds could exert protective effect in at least one cell model. Notably, purpurin exerted protective effect in three cell models and significantly improved the cognitive learning and memory functions, reduced the oxidative stress injuries and neuroinflammation, and enhanced the synaptic plasticity and neurotrophic effect in the brain of d-galactose-treated rats. In this study, AD-related natural compounds were identified via network proximity and gene enrichment analyses. In vivo and in vitro experiments revealed the therapeutic potential of purpurin for AD treatment, laying the foundation for further in-depth research and providing valuable information for the development of novel anti-AD drugs.
OBJECTIVE: Observational studies have shown a higher prevalence of Sjogren's syndrome (SjS) in patients with primary biliary cholangitis (PBC) than in the healthy population, but whether this correlation is causal needs further confirmation. This study aimed to investigate the bidirectional causal relationship between PBC and SjS using Mendelian randomization (MR) analysis.
MATERIALS AND METHODS: We used pooled data from a large-scale genome-wide association study (GWAS) to select mutually independent genetic loci associated with PBC and SjS in people of European ancestry as instrumental variables (IVs). The causal association between PBC and SjS was analyzed by MR analysis using inverse variance weighting (IVW) and weighted median methods, and the ratio of ratios (OR) was used as an evaluation index. In addition, sensitivity analyses, including Cochran's Q test, MR-PRESSO, MR-Egger intercept test, and leave-one-out test, were performed to ensure the stability of the results.
RESULTS: A total of 20 validated IVs were selected for PBC, and the number of IVs for SjS was seven. Positive MR analysis showed that genetically predicted PBC was significantly associated with the risk of SjS (IVW OR=1.174, 95% CI: 1.107-1.246, p<0.001). The weighted median method further confirmed this result (OR=1.146, 95% CI: 1.053-1.247, p=0.016). Inverse MR analysis showed that genetic susceptibility to SjS also increased the risk of PBC (IVW OR=1.737, 95% CI: 1.280-2.357, p<0.001), and this result was also confirmed by the weighted median method (OR=1.398, 95% CI: 1.120-1.746, p=0.003).
CONCLUSIONS: Our study found that genetically predicted SjS increased the risk of PBC and vice versa in a European population. This may shed light on the etiology of PBC and the management of patients with SjS.
The invention belongs to the technical field of Chinese herbal medicines, and discloses a composition for treating hyperglycemia and a preparation method thereof. The composition is prepared into final product with optimal compatibility, and has effects of invigorating spleen, regulating stomach function, regulating qi-flowing, and eliminating dampness. Soothing liver, promoting bile flow, dredging meridian passage, clearing away heat, and dispersing pathogen accumulation. Eliminating phlegm and removing dampness. It is suitable for treating diabetes, heart disease, pulmonary tuberculosis, leg edema, and foot edema. The formula function is as follows: fire tonifies kidney water, warms the fire of the gate of life, opens liver depression, meets heart and kidney, guides fire to origin, and enables water vapor to be self-eliminated and qi and blood to be smooth. The preparation method of the composition is simple and convenient, and the obtained finished product has stable dosage form and is convenient to take.
Participants will be monitored during the intervention using a Radical-7 Pulse CO-Oximeter to instantly determine the pleth variability index (PVI). If the PVI is more than 14% for at least 5 minutes, 250 ml of gelofusine solution will be given over 10 minutes.
The invention provides a method of attaching peptides containing a RGD adhesion peptides, to a solid surface through a hydrophobic domain, and peptides so attached. The hydrophobic domain can contain either hydrophobic amino acids, such as leucine, valine, isoleucine or phenylalanine, or fatty acids, such as, for example, myristic acid, palmitic acid, arachidic acid or other fatty acids. Additionally, spacers, such as amino acids, between the hydrophobic domain and the biologically active domain can improve the presentation of the biologically active site. Specific peptides of the invention include GRGDSPASSKG4?SRL6?RNH2?; GRGDSPASSKS3?RL6?RNH2?; AND GRGDSPASSKSSKRL6?RNH2?. Coupled to a solid surface, such peptides can be used to detect the presence of a ligand complementary to the biologically active site.
Of the total number of Infliximab-treated patients in RA and Ps clinical studies, 256 (9.6%) were 65 years old and over, while 17 (0.6%) were 75 years old and over. In these trials, no overall differences in safety or effectiveness were observed between geriatric patients (patients ≥ 65 years old) and younger adult patients (patients 18 to 65 years old). However, the incidence of serious adverse reactions in geriatric patients was higher in both Infliximab and control groups compared to younger adult patients.

Of the total number of Infliximab-treated patients in CD, UC, AS, and PsA clinical studies, 76 (3.2%) were 65 years old and over, while 9 (0.4%) were 75 years old and over. In the CD, UC, AS, and PsA studies, there were insufficient numbers of geriatric patients to determine whether they respond differently from younger adults .

The incidence of serious infections in Infliximab-treated geriatric patients was greater than in Infliximab-treated younger adult patients; therefore close monitoring of geriatric patients for the development of serious infections is recommended [see Warnings and Precautions (5.1), and Adverse Reactions (6.1)].
The invention provides a polypeptide targeting CD47 and application thereof. The polypeptide of the invention can specifically recognize and bind to CD47 protein. The invention also provides the polypeptide, a bivalent body, a multivalent body and a polypeptide conjugate formed by the polypeptide, and application of the polypeptide in preparing a diagnosis and treatment agent and an imaging agent for targeting and killing tumor cells. The polypeptide is synthesized by a chemical method, is simple to prepare, strong in specificity, high in selectivity, safe and reliable, overcomes the defects of long production cycle of an antibody biological preparation and the like, and can be used for preparing a cancer-targeted probe. The invention can carry out immune blocking on the CD47 protein by an immunotherapy method, thereby activating the recognition and phagocytosis of an in-vivo immune system on tumor cells, effectively inhibiting the growth and the metastasis of tumors and realizing good anti-tumor effect. The polypeptide of the invention can provide effective clinical basis and application value for immunotherapy.
Our goal is to identify an artificial intelligence algorithm that can be run on lung radiographs in patients with influenza / respiratory viral symptoms who come to the emergency department / triage. This algorithm aims to identify the radiographs of patients with COVID-19 and those with influenza pneumonitis, with accuracy verified by COVID-19 tests.
SLS009 (60 mg QW) in combination with venetoclax and azacitidine in patients with r/r AML who have relapsed on or are refractory to venetoclax-based regimens. US study sites only. (Cohort completed).
The invention relates to Ejiao Guiqi Granules and a manufacturing method of thereof. The Ejiao Guiqi granules belong to health foods and have the function of improving alimentary anemia. The Ejiao Guiqi granules comprise the following active ingredients by weight: 30-80 parts of donkey-hide gelatin; 20-50 parts of codonopsis pilosula; 10-40 parts of padix rehmanniae preparata; 20-40 parts wolfberry fruit; 20-40 parts of rhizoma atractylodis macrocephalae; 1-4 parts of vitamin C; 0.5-2 parts of ferrous lactate; and 750-1000 parts of white sugar. The Ejiao Guiqi granules are manufactured through the processes such as melting the donkey-hide gelatin by heat, boiling codonopsis pilosula, padix rehmanniae preparata, wolfberry fruit and hizome atractylodis macrocephalae with water for extraction, performing vacuum concentration, ethanol precipitation and ethanol recovery, mixing, granulating, drying, grading, packing and the like. The Ejiao Guiqi granules have the characteristics of scientific formulation, reasonable process and the like. Through human body tests, the Ejiao Guiqi granules are proven to have functions of improving alimentary anemia and promoting health, have no adverse effect on health, and are safe and reliable to eat.
OBJECTIVE: Patients with Alzheimer's disease (AD) have diffuse brain atrophy, but some regions, such as the anterior cingulate cortex (ACC), are spared and may even show increase in size compared to controls. The extent, clinical significance, and mechanisms associated with increased cortical thickness in AD remain unknown. Recent work suggested neural facilitation of regions anticorrelated to atrophied regions in frontotemporal dementia. Here, we aim to determine whether increased thickness occurs in sporadic AD, whether it relates to clinical symptoms, and whether it occur in brain regions functionally connected to-but anticorrelated with-locations of atrophy.
METHODS: Cross-sectional clinical, neuropsychological, and neuroimaging data from the Alzheimer's Disease Neuroimaging Initiative were analyzed to investigate cortical thickness in AD subjects versus controls. Atrophy network mapping was used to identify brain regions functionally connected to locations of increased thickness and atrophy.
RESULTS: AD patients showed increased thickness in the ACC in a region-of-interest analysis and the visual cortex in an exploratory analysis. Increased thickness in the left ACC was associated with preserved cognitive function, while increased thickness in the left visual cortex was associated with hallucinations. Finally, we found that locations of increased thickness were functionally connected to, but anticorrelated with, locations of brain atrophy (r = -0.81, p < 0.05).
INTERPRETATION: Our results suggest that increased cortical thickness in Alzheimer's disease is relevant to AD symptoms and preferentially occur in brain regions functionally connected to, but anticorrelated with, areas of brain atrophy. Implications for models of compensatory neuroplasticity in response to neurodegeneration are discussed. ANN NEUROL 2024;95:929-940.
This study adopted an experimental research design to explore the effects of a warm water foot bath program on fatigue, sleep, and heart rate variability in patients with heart failure. The research subjects are cardiology outpatients at two medical centers in northern China (Taipei and New Taipei City). It is expected to recruit 76 research subjects (38 in the control group and 38 in the experimental group). Pre-test data collection includes basic personal information, subjective sleep quality and fatigue level questionnaires, and wearing an actigraph on the wrist. Patients were assigned to an experimental group and a control group based on random assignment results. The control group received routine care and wore an actigraph. In addition to routine care and wearing an actigraph, the experimental group also received warm foot baths for 4 weeks, one hour before going to bed every night. (7-9PM), the temperature is 42°C for 20 minutes, and the water depth is 10 cm above the ankle joint. Both groups receive weekly phone calls to confirm wearing the actigraph and performing warm water foot baths. Post-test data were collected in the second and fourth weeks, including subjective sleep quality and fatigue level questionnaires. After the four weeks, the researchers collected and analyzed physiological measurements: sleep quality-sleep time and efficiency, and heart rate variability index. Research tools include basic information sheets, actigraphy, warm water foot bath machines, Pittsburgh Sleep Quality Scale, and Piper Fatigue Scale. The collected data were processed and analyzed using SPSS 26.0 statistical software. Warm water foot bath is a local hot compress, which is non-invasive and simple to operate. It has the effect of relieving sleep and fatigue of patients with heart failure. It is suitable for patients with heart failure during hospitalization or at home.We hope it will be helpful to clinical care practice, education and research.
Plasma exchange (PE) is a standardized and safe therapeutic procedure, used in the treatment of various diseases that require rapid and prolonged elimination of endogenous and exogenous substances, with deleterious effects on the function of different organs and systems. The efficacy and safety of PE has been demonstrated in patients with fulminant hepatitis (FH), an entity characterized by an exacerbated inflammatory response, multi-organ failure, and high short-term mortality. In FH, plasma exchange improves systemic inflammation, prevents organ failure and renal support requirements, and improves survival. Such treatment eliminates important endogenous and exogenous inducers of the systemic inflammatory response (PAMPs and DAMPs), proinflammatory mediators (cytokines and ROS), and other biologically active substances (nitric oxide, prostaglandins, and bradykinin) that are involved in the pathogenesis of organ failure. Several case reports also suggest that PE is an effective rescue therapy in critically ill patients with influenza A (H1N1). However, the efficacy of PE has not been evaluated in critically ill patients with COVID-19 disease.
PROBLEM TO BE SOLVED: To design a make-up cosmetic such as foundation looked natural, by approximating the color of a make-up cosmetic to a spectrophotometric curve of skin. SOLUTION: The design of the color of make-up cosmetic is made so that, in the spectrophotometric curve measured by packing into a color measuring cell, all points except the points at 600nm and 540nm exist below a straight line connecting a point at 600nm and a point at 540nm on the curve. A naturally looking color is designed by using this designing method to prepare a make-up cosmetic. Preferably, the make-up cosmetic is mixed with organic color matters of red to yellow. The outer layer of the red part contains powder having a semitransparent layer, the powder is obtained by coating extender powder with a red coloring matter and further coating semitransparent powder. The color designing method can be applied to a make-up cosmetic such as foundation, control color, under make-up, spot cover and highlight.
The Developmental Origins of Health and Disease hypothesis (DOHaD) proposes that growth during the prenatal period might play a critical role in health, affecting the development of diseases, such as osteoporosis. Bone health is particularly affected by human behaviors when sports participation constitutes the main manifestation of physical exercise. The aim of this study is to analyze the relationship between birth weight (BW) and bone mineral content (BMC) among adolescents, as well as to identify if sports participation and maturity can affect this relationship. The sample was composed of adolescents with ages ranging from 11 to 18 years, stratified according to normal birth weight (n = 331), low birth weight (n = 36), and macrosomia (n = 47), extracted from a wider cross-sectional study (ABCD Growth Study). BW was self-reported by the adolescent's parent. Sports participation was assessed by face-to-face interview. BMC was assessed using dual-energy X-ray absorptiometry. In the multivariate models, the relationships between BW and BMC remained non-significant, while sports participation was significantly related to BMC on lower limbs among boys (r = 0.154; p value = .001) and BMC of upper limbs among girls (r = 0.124; p value = .044). APHV was related to BMC of upper limbs among boys (r = 0.137; p value = .001). In conclusion, BMC was not affected by BW, while this phenomenon seems to be significantly affected by the positive impact of sports participation and maturation on it.
A bone cement formulation comprising: (a) magnetic calcium phosphate nanoparticles present in an amount of 5.0-95 wt. % and having a largest linear dimension of 150 nm to 50 microns; (b) polymerizable acrylate monomer present in an amount of 5.0-95 wt. %; and (c) polyacrylate polymer present in an amount of 0-80 wt. % and having a largest linear dimension from 5.0 to 500 microns. Upon exposure to an alternating magnetic field the formulation is heated which results in polymerization of the acrylate monomer component. The formulation may also be polymerized via the use of chain polymerization initiators.
Novel pro-drugs to new and unnatural dipeptoids of  alpha -substituted Trp-Phe derivatives useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the dipeptoids are antianxiety agents and antiulcer agents. They are agents useful for preventing the response to the withdrawal from chronic treatment or with use of nicotine, diazepam, alcohol, cocaine, caffeine, or opioids. The pro-drugs are also useful in treating and/or preventing panic attacks. Also disclosed are pharmaceutical compositions and methods of treatment using the pro-drugs as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject pro-drug compounds in diagnostic compositions.
PURPOSE:To obtain a growth promotion agent for animal effective also in improving feed conversion of animal and remedying bacterial diseases, by using specific glycopeptides as active components. CONSTITUTION:The objective agent contains the compound of formula I (R is group of formula II, formula III or H), i.e. PA-42867-A (R is group of formula II), des-(4-epivancosaminyl) PA-42867-A (R is group of formula III), des-(4- epivancosaminyl-0-glucosyl) PA-42867-A (R is H) or its salt, as an active component. The compound can be produced by the culture of Nocardia sp.-PA-42867 (FERM BP-1230). It may be used as bacterial cell containing the same or as an extracted and purified material, etc. In the case of using the agent as an additive for feed, it is used at a rate of 0.5-100ppm of the compound in the feed.
The present invention relates to a green plum beverage and a preparation method thereof. Plum and white sugar are processed by dry leaching according to the weight ratio of 1: 0.4 to 0.7 so as to prepare plum leaching juice, and the beverage is prepared by 12 to 22% of the plum leaching juice, 0.05 to 0.5% of honey and purified water as the rest. The present invention has the preparation method that green plum or yellow plum raw materials are processed via the procedures of room temperature stacking fermentation, cleaning, airing, entering a pool, white sugar leaching in interlayers, plum leaching juice separation, adjuvant materials and water addition, germicidal treatment, split charging and product finishing. The green plum beverage of the present invention completely removes saline flavor and reserves the unique natural flavor of the green plum, and the beverage is directly prepared by the leaching liquor of the plum and the white sugar. The green plum avoids pollution brought by the technical processes of stir, filtration, etc., the production technique is simple and practical, and production cost is low. The green plum beverage can quenching thirst with sour and sweet taste and are popular with customers, and the present invention provides a new practical technique for the deep processing, development and utilization of the green plum.
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
PURPOSE: To explore the correlation between preoperative cephalic vein pathological types and the maturation of autogenous arteriovenous fistula (AVF) in patients with chronic kidney disease (CKD), providing new ideas and methods for clinical prediction of fistula maturation.
METHODS: A retrospective analysis was performed in 80 patients who underwent AVF creation surgery from June 2021 to June 2023 at our hospital. Patients were followed up for 6 months. Patients were classified into the mature group (n = 57) and the power loss group (n = 23) based on the AVF maturation status. Preoperative excised venous tissues were examined using Masson's trichrome staining to compare the intimal area (Ia), medial area (Ma), lumen diameter (Ld), average intimal thickness (Avg It), and average medial thickness (Avg Mt), along with the calculations and comparisons of Ia/Ma, Avg It/Avg Mt ratios. Factors influencing AVF power loss were identified using the multifactorial logistic regression analysis.
RESULTS: Ia, Ia/Ma, and Ld were lower in the power loss group compared to the mature group (P < 0.01). No significant difference was found in Avg Mt and Avg It/Avg Mt levels between the two groups (P > 0.05). The level of Avg It was higher in the power loss group (P < 0.05). Avg It was a risk factor (P < 0.001), while Ld was a protective factor for AVF power loss (P < 0.05).
CONCLUSION: The levels of Avg It and Ld in preoperative cephalic vein tissue before AVF formation were correlated with AVF power loss. Early monitoring may improve therapeutic outcomes and prognosis of patients with stage 5 CKD.